Piramal Pharma Navigates Market Shifts with Revenue Growth

Chairperson Nandini Piramal described the fiscal year as a transitional period, noting that execution improvements across the company's three main business segments helped offset broader market volatility. The contract development and manufacturing arm, Piramal Pharma Solutions, remains the primary engine, accounting for 55% of total revenue and supporting a client base of more than 500 global firms. The company reinforced this division with a US$90 million investment targeted at expanding sterile injectables and payload linker capabilities.

Elsewhere, the Critical Care unit solidified its market standing by retaining the top position in the US Sevoflurane sector while integrating the newly acquired Kenalog portfolio. Simultaneously, the consumer healthcare business expanded its reach, launching 31 new products and achieving 24% growth in its core 'Power Brands.' Operational integrity accompanied these commercial gains; the company cleared 38 regulatory inspections, including three USFDA audits, without receiving any Official Action Indicated observations. Sustainability efforts also advanced, with the firm reporting a 22.6% reduction in greenhouse gas emissions from its FY2022 baseline, supported by a workforce of over 7,285 employees who maintained a record of zero fatalities for the fifth consecutive year.